Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Creating J&J's Cardiology Franchise: An Interview with Marv Woodall

Executive Summary

In this interview, Marv Woodall, the architect of Johnson & Johnson's cardiology business, reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why--despite all their success--stents have not met their original goal.

You may also be interested in...



Prescient Medical's Dual Approach to Vulnerable Plaque

Vulnerable plaque caught investors' and entrepreneurs' attention several years ago as the mysterious cause of more than half of all cases of sudden cardiac death, most of which occurs in people with no history of heart disease. Several companies were launched and much money invested with little to show for it. One major problem: vulnerable plaque requires new tools both to diagnose and treat the condition, which proved to be bigger hurdles than most start-ups can overcome. Prescient was launched by an experienced device management team and is applying Raman spectroscopy, to coronary disease as the basis of its diagnostic tool, and is using a shield-not a stent-for its therapeutic device.

Seven Talking Points At ASH 2019

US Biosimilar Sponsors Seek Off-The-Record Discussions

Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions without written record; negotiations for BsUFA III may be opportunity to create such a process.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel